Q-omics provides the consensus-scored H2BP9 profile across patient tissues and cancer cell-line models. H2BP9 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, H2BP9 is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, H2BP9 RNA expression shows 12,893 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight ACC, HNSC, and LAML as cancer lineages where H2BP9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for H2BP9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes H2BP9 survival associations across molecular data types. H2BP9 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible H2BP9 RNA expression–survival associations across cancer types. High H2BP9 expression shows unfavorable associations in ACC, KIRC, UVM and STAD, but favorable associations in BLCA and PAAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for H2BP9 RNA expression.
This table summarizes H2BP9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for H2BP9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. H2BP9 shows lower tumor expression in KICH and higher tumor expression in HNSC, CHOL, UCEC, BLCA and LUSC. The HNSC box plot shows higher H2BP9 RNA expression in tumor versus normal tissue (log2 FC = +0.151, t-test p < 0.001).
This table shows molecular features associated with H2BP9 in patient tissues and cancer cell lines. In patient samples, H2BP9 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
